Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 20/20 | 0.70 |
| ▸ | GRIN2A | Q12879 | 20/20 | 0.70 |
| ▸ | GRIA2 | P42262 | 10/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20129429 | 0.92 | GRIN1 (0.71) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL20129437 | 0.82 | GRIN2A (1.00) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL20129425 | 0.81 | GRIN1 (1.00) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL18161046 | 0.80 | GRIN1 (1.00) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL20129427 | 0.78 | GRIN2A (1.00) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL20129434 | 0.78 | GRIN2A (1.00) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL20129426 | 0.77 | GRIN2A (1.00) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL20129433 | 0.76 | GRIN2A (1.00) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL20129430 | 0.75 | GRIN2A (1.00) | GRIN1GRIN2AGRIA2 | |
| SCHEMBL18161044 | 0.75 | GRIN2A (0.81) | GRIN1GRIN2AGRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531696-B | Pyridopyrimidinones as NMDA receptor modulators and their use | 豪夫迈·罗氏有限公司 | 2021-03-16 | — | — | CN | claimed |
| EP-3283487-B1 | PYRIDOPYRIMIDINONES AND THEIR USE AS NMDA RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2019-10-16 | — | — | EP | claimed |
| US-10280165-B2 | Pyridopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180127414-A1 | PYRIDOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127414-A1 | PYRIDOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127414-A1 | PYRIDOPYRIMIDINONES AND METHODS OF USE THEREOF | PDXK, XDH, PNPO | GRIN1 1955/4885GRIN2A 2896/4885GRIA2 2803/4885 |
| US-10280165-B2 | Pyridopyrimidinones and methods of use thereof | PDXK, XDH, PNPO | GRIN1 1955/4885GRIN2A 2896/4885GRIA2 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.